Jianfan Bio: The plasma separator was certified by the European Union MDR, and Jianfan Bio announced that Jianfan Blood Purification Company, a wholly-owned subsidiary, recently received a notice from the EU announcement agency that its plasma separator was certified by the European Union MDR in accordance with the EU Medical Devices Regulation 2017/745, and can be sold in EU countries and other countries that recognize the EU CE certification.Guotai Junan: The long-term incremental "option" brought by humanoid robots is expected to help the valuation of the rare earth sector rise. When looking forward to the strategy of the rare earth sector in 2025, Guotai Junan said that the market had expected that with the slowdown in the growth of core demand power such as new energy vehicles and wind power in the future, the demand for rare earth markets is under downward pressure. However, we expect that the rising consumption of magnetic materials for new energy vehicles and the warming demand for wind power are still expected to support the basic demand growth, and the demand for equipment renewal that began to land in 2024 is expected to become a new driving force for rare earth demand. On the supply side, an orderly pattern of domestic supply has been established, with many overseas planning increments but slow actual volume, and continuous supply-side constraints. In addition, the long-term incremental "options" brought by humanoid robots are also expected to help the valuation of the plate rise.US President-elect Trump: Opposing Ukrainian armed forces to attack Russia with US long-range missiles has further escalated the conflict.
Kweichow Moutai: The company will hold a briefing on the third quarter of 2024 from 15: 00 to 16: 00 on Tuesday, December 17, 2024.Daiwa raised Tesla's target price to $420.The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.
Xinwangda: The subsidiary and Xiamen Tungsten Xinneng signed the Framework Agreement on Strategic Cooperation for Solid-State Batteries. Xinwangda announced that the subsidiary Xinwangda Power and Xiamen Tungsten Xinneng signed the Framework Agreement on Strategic Cooperation for Solid-State Batteries, and the two sides will carry out extensive and in-depth cooperation on research and development, mass production and market development of a series of new energy battery materials for solid-state batteries around their respective development strategies. The cooperation contents include the development of cathode materials for solid-state batteries, the development of electrolytes and related materials for solid-state batteries, the cooperative development of solid-state batteries and industrial cooperation.Yiwangyichuang: Shareholder Zhang Fan plans to reduce his shareholding by no more than 1%. Yiwangyichuang announced that shareholder Zhang Fan, who holds more than 5% of the company's shares, plans to reduce his shareholding by centralized bidding and/or block trading, and the number of shares to be reduced is no more than 2,369,400, accounting for 1.00% of the company's total share capital. The reduction period is from January 6, 2025 to April 4, 2025. The price range of reduction will be determined according to the market price and trading method at the time of reduction. The reason for Zhang Fan's reduction is based on his own capital demand, and the shares come from the shares issued before the initial public offering, the shares transferred due to equity distribution and the shares transferred by agreement.Kweichow Moutai: The company will hold a briefing on the third quarter of 2024 from 15: 00 to 16: 00 on Tuesday, December 17, 2024.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
12-13
Strategy guide 12-13